Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 7:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 117 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Omacor (omega-3-acid ethyl esters) Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Nutritional Supplements and Hormonal Manipulations for Breast Cancer Prevention

NCT00723398
View directory record Official record
Conditions
Breast Cancer
Interventions
Lovaza 4gm oral, Raloxifene 60 Mg Oral Tablet, Raloxifene 30 Mg Oral Tablet, Lovaza 4gm & Raloxifene 30mg
Dietary Supplement · Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
35 Years to 70 Years · Female only
Enrollment
266 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 1, 2018 · Synced Oct 5, 2026, 7:07 AM EDT
Completed Phase 4 Interventional Results available

Human Immunodeficiency Virus (HIV), Arterial Dysfunction, Lipids, Lovaza (HALO) Trial

NCT00795717
View directory record Official record
Conditions
Cardiovascular Disease, HIV Infection
Interventions
Lovaza, Placebo
Drug
Lead sponsor
Tufts University
Other
Eligibility
18 Years to 65 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Oct 5, 2026, 7:07 AM EDT
Completed Phase 4 Interventional Results available

The Impact of Omega Three Fatty Acids on Vascular Function in HIV

NCT01041521
View directory record Official record
Conditions
High Triglyceride Level, HIV Infection
Interventions
Lovaza
Drug
Lead sponsor
Tufts University
Other
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 11, 2020 · Synced Oct 5, 2026, 7:07 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of Vitamin D and Omega-3 Supplementation for Preventing Diabetes

NCT01633177
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Vitamin D3, Omega-3 fatty acid (fish oil), Vitamin D3 placebo, Fish oil placebo
Dietary Supplement · Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
50 Years and older
Enrollment
22,220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 5, 2026, 7:07 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

The Effects of Omega-3 Fatty Acids on Aspirin Resistance

NCT00771914
View directory record Official record
Conditions
Increased Drug Resistance
Interventions
Aspirin, Lovaza, Both Aspirin and Lovaza, Placebo
Drug · Other
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 50 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 6, 2012 · Synced Oct 5, 2026, 7:07 AM EDT
Withdrawn Not applicable Interventional

Lovaza Therapy of Peripheral Arterial Disease

NCT00569686
View directory record Official record
Conditions
Peripheral Artery Disease
Interventions
lovaza, placebo
Drug
Lead sponsor
University of Virginia
Other
Eligibility
40 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 7, 2018 · Synced Oct 5, 2026, 7:07 AM EDT
Not listed Phase 4 Interventional

Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease

NCT00941642
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease
Interventions
Lovaza, placebo control
Drug
Lead sponsor
Huntington Medical Research Institutes
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Jun 10, 2010 · Synced Oct 5, 2026, 7:07 AM EDT
Completed Phase 4 Interventional Results available

Evaluating the Effectiveness of Fish Oil Supplements at Reducing the Recurrence of Atrial Fibrillation

NCT00552084
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Fish oil, Placebo
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
21 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 3, 2014 · Synced Oct 5, 2026, 7:07 AM EDT
Withdrawn Phase 2 Interventional

Omacor for Perimenopausal Depression

NCT00517972
View directory record Official record
Conditions
Depression
Interventions
Omacor (omega-3-acid ethyl esters)
Drug
Lead sponsor
University of Arizona
Other
Eligibility
40 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 29, 2012 · Synced Oct 5, 2026, 7:07 AM EDT
Completed Phase 4 Interventional Results available

Omega-3 Fatty Acids (Lovaza) for Second Generation Antipsychotic-Associated Hypertriglyceridemia

NCT00833976
View directory record Official record
Conditions
High Triglycerides, Hypercholesterolemia, Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
Interventions
Lovaza
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 5, 2026, 7:07 AM EDT
Completed Phase 3 Interventional Results available

The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)

NCT00069784
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
insulin glargine (HOE901), omega-3 polyunsaturated fatty acids (PUFA), placebo, reusable pen device for insulin injection
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
50 Years and older
Enrollment
12,537 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Oct 5, 2026, 7:07 AM EDT
Not listed No phase listed Observational

Effects of Omega-3 Fatty Acids on Platelets in Patients With Coronary Artery Disease With Hypertriglyceridemia

NCT01086163
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Omacor, omega-3 fatty acids in CAD patients
Drug
Lead sponsor
HeartDrug Research LLC
Other
Eligibility
50 Years to 60 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Towson, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 12, 2010 · Synced Oct 5, 2026, 7:07 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

VITamin D and OmegA-3 TriaL: Effects on Bone Structure and Architecture (VITAL)

NCT01747447
View directory record Official record
Conditions
Bone Density, Body Composition, Bone Health
Interventions
Vitamin D3 placebo, Fish oil placebo, omega-3 fatty acids (fish oil), Vitamin D3
Dietary Supplement
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
50 Years and older
Enrollment
771 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 5, 2026, 7:07 AM EDT
Completed Phase 3 Interventional Results available

A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin

NCT01492361
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
AMR101, Placebo, Statin therapy
Drug
Lead sponsor
Amarin Pharma Inc.
Industry
Eligibility
45 Years and older
Enrollment
8,179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
176
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 154 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2022 · Synced Oct 5, 2026, 7:07 AM EDT
Terminated Phase 3 Interventional Results available

The Effect of Omega-3 Polyunsaturated Fatty Acids in Congestive Heart Failure

NCT00944229
View directory record Official record
Conditions
Heart Failure
Interventions
LOVAZA (Omega-3), Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 25, 2016 · Synced Oct 5, 2026, 7:07 AM EDT
Terminated Phase 1 Interventional

Study of Fish Oil to Reduce ALT Levels in Adolescents

NCT00694746
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease, Fatty Liver
Interventions
Omega-3-acid ethyl esters, Placebo
Drug
Lead sponsor
Boston University
Other
Eligibility
13 Years to 17 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 29, 2016 · Synced Oct 5, 2026, 7:07 AM EDT
Completed Not applicable Interventional Results available

Effects of Prescription Omega-3 Acids on Glucose and Lipoprotein Lipids in Subjects With Hypertriglyceridemia

NCT01034540
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
POM3, Placebo
Drug
Lead sponsor
Provident Clinical Research
Other
Eligibility
18 Years to 79 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Addison, Illinois
Source: ClinicalTrials.gov public record
Updated May 30, 2024 · Synced Oct 5, 2026, 7:07 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Go Fish: Omega-3 Fatty Acid Supplementation in Diabetes-Related Kidney Disease

NCT01092390
View directory record Official record
Conditions
Diabetes
Interventions
Lovaza (fish oil)
Dietary Supplement
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 30, 2012 · Synced Oct 5, 2026, 7:07 AM EDT
Completed Not applicable Interventional Results available

Effects of Fatty Acid Delivery on Heart Metabolism and Function in Type 2 Diabetes (T2DM

NCT00577590
View directory record Official record
Conditions
Diabetes Mellitus, Type II
Interventions
Metformin, Rosiglitazone, Lovaza
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 31, 2018 · Synced Oct 5, 2026, 7:07 AM EDT
Completed Phase 1 Interventional Results available

An Open-Label Crossover Study to Compare the Relative Bioavailability, Efficacy and Safety of Epanova® and Lovaza® in Men and Women With a History of Pancreatitis

NCT02189252
View directory record Official record
Conditions
Severe Hypertriglyceridemia
Interventions
Epanova, Lovaza
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
3
States / cities
Kansas City, Kansas • Cincinnati, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 20, 2016 · Synced Oct 5, 2026, 7:07 AM EDT
Completed Phase 4 Interventional Results available

A Second Open-Label Extension of a Double-Blind, Parallel, Phase IV Study to Assess the Efficacy and Safety of Adjunctive Lovaza® (Formerly Known as Omacor®) Therapy in Hypertriglyceridemic Subjects Treated With Antara™

NCT00891293
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
Antara (fenofibrate) + Lovaza (omega-3-acid ethyl esters)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 79 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
32
States / cities
Spring Valley, California • Washington D.C., District of Columbia • Coral Gables, Florida + 27 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2011 · Synced Oct 5, 2026, 7:07 AM EDT
Terminated Phase 4 Interventional

Omega-3 Fatty Acids as an Adjunctive Therapy for Stimulants in Children With ADHD

NCT01778647
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Stimulants plus Lovaza, Stimulants plus placebo
Dietary Supplement · Drug
Lead sponsor
Antonios Likourezos
Other
Eligibility
6 Years to 15 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Dec 14, 2023 · Synced Oct 5, 2026, 7:07 AM EDT
Completed Not applicable Interventional Results available

Vascular and Lipid Effects of Omega-3 Fatty Acids in People With Moderately Elevated Triglycerides

NCT00504309
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
4/day of 4g P-OM3 capsules, 4/day of 1g P-OM3 capsules, Corn Oil Placebo, 4 capsules/day for 8 weeks
Drug
Lead sponsor
Penn State University
Other
Eligibility
21 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Oct 5, 2026, 7:07 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Effects of Fish Oil and Red Wine on Oxidative Stress Biomarkers

NCT00682318
View directory record Official record
Conditions
Healthy
Interventions
Fish Oil, Safflower Oil, Ethanol, Omega-3 polyunsaturated fatty acids, Omega-6 polyunsaturated fatty acid
Drug · Dietary Supplement
Lead sponsor
Carsten Skarke, MD
Other
Eligibility
21 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 5, 2026, 7:07 AM EDT